Navigation Links
Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
Date:5/30/2008

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it is implementing the next step in its ongoing effort to focus its resources on the company's clinical and later-stage discovery programs. This effort includes an immediate workforce reduction of approximately 15 percent through attrition and termination of positions as well as a decrease in other expenses through improved operational efficiencies and increased financial discipline. The company's annual operating expenditures are expected to decrease by at least $10 million in 2009.

"We believe that, with the recent announcement of our positive Phase 2a results for PS433540 (DARA), it is the appropriate time to continue executing our plan to allocate a greater share of our resources towards our later-stage programs," said Joseph A. Mollica, Ph.D., Chairman of the Board of Directors and Interim President and Chief Executive Officer of Pharmacopeia. "We are grateful for the contributions of the highly talented individuals whose positions are impacted by these decisions and wish them success in their future endeavors."

"In order to maximize shareholder value it is essential that we focus our efforts on the programs that can provide the greatest return. In addition to PS433540, these programs include: PS178990, our Selective Androgen Receptor Modulator (SARM) which we believe will progress into Phase 2 testing in the first half of 2009; PS031291, our oral CCR1 development candidate for which we intend to initiate clinical development for the treatment of rheumatoid arthritis in early 2009; and our JAK3 program for the topical treatment of psoriasis which we expect to enter preclinical development in 2009. Discovery research remains a core strength of Pharmacopeia and will be increasingly focused on the discovery and advancement of clinical candidates that we can indep
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Shire plc (LSE: SHP,NA...ical company, today,announced that it has submitte...lucerase alfa, the company,s enzyme replacement th...aucher disease. This is the third marketing,applic...ed, with previous,submissions in the United States...
(Date:11/24/2009)...Nov. 24 Genomic Health, ...cott, Genomic Health,s Executive Chairman, will pr... Conference in New York City on Tuesday, December ...e and subsequently archived webcast of the present...omic Health,s website at http://investor.genomich...
(Date:11/24/2009)...nnects Customers with Partners Validated to Proces...roducts , Ottawa, ON (PRW...provider of products for biological sample collect...d its new global partner program. The program offe...ner community and is designed to help partners sca...
(Date:11/24/2009)...Newswire-FirstCall/ -- Cell Therapeutics, Inc. (CT...at the 21st Annual Piper Jaffray Health Care Confe...009, at the New York Palace Hotel. ,, CTI wil...tern Time in Holmes 1 (4th Floor). A live audio we...www.celltherapeutics.com , and it will also be ava...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...Inc.,(Nasdaq: BHRT ) today announced that it has ...ommon stock to the Nasdaq Capital Market. The Comp...sdaq Global Market to The,Nasdaq Capital Market at...8. The Nasdaq Capital Market is a tier of the Nasd...capitalization requirement than the Global,Market ...
...0 Miltenyi Biotec has,acquired Medic Tools AG fro... Biotec strengthens the portfolio in the area of s...y devices and techniques fit,perfectly into the pr...,offered by Miltenyi Biotec", Miltenyi Biotec CEO ...ent and CEO of Medic Tools AG, stated in a,conjoin...
... for The Joint,Commission survey process within th...virtually all internal services used to support pa...audited. As a result, a,healthcare institution mus...proceed in almost any direction and to involve any...iew sessions, if done properly, can dramatically,i...
Other Biology Technology:Bioheart, Inc. to Transfer to Nasdaq Capital Market 2Miltenyi Biotec GmbH Acquires Medic Tools AG 2White Paper Helps Hospitals Prepare Staff for Joint Commission Environment of Care Interview Sessions 2
(Date:11/23/2009)... Farmington, CT Current research suggests that a ...sease. The related report by Nichols et al, "Uniq...a New Class of TLR2 Ligands Capable of Enhancing A...f The American Journal of Pathology . , Multipl...m attacks the brain and spinal cord, affects nearl...
(Date:11/23/2009)..., AMES, Iowa - The only swine vaccine available f...ne herd infected with the virus. The vaccination m...ne herd diagnosed with the pandemic flu., Iowa S... science, developed the vaccine this summer and ha...s in Iowa, Kansas and Illinois for several weeks.,...
(Date:11/23/2009)... MADISON, WI, November 16, 2009 -- A USDOE and USD...opland, idle cropland, and cropland pasture could ...f perennial grasses, such as switchgrass, from whi... feedstock. Economically viable production of a pe...uantities of biomass are removed annually is expec...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 1Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 2Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 3China Pharma Holdings Inc to Present at the Roth China Conference on October 14 at 12 3A00 pm ET 14434 1Sequella Obtains Funding to Continue Expansion of its Anti infectives Pipeline 14432 1Sequella Obtains Funding to Continue Expansion of its Anti infectives Pipeline 14432 2Sequella Obtains Funding to Continue Expansion of its Anti infectives Pipeline 14432 3
...netic changes in bacteria may ultimately help drug...ria that can become resistant to antibiotics. , Th... ribosome, a tiny protein-making factory residing ...ics alter a ribosome,s ability to make proteins, s...ant professor of microbiology at Ohio State Univer...
...rice of having one,s personal genome sequenced jus... about $2.2 million, and the goal is to reduce the...alized prevention and treatment realistic. , The s...y developed by Harvard Medical School (HMS) resear..., and their colleagues, reported on August 4 in th...
... protein in different subtypes of avian flu viruse...tadine in H5N1 occurs worldwide, but is especially...stance to the antiviral drug amantadine is spreadi...5N1 subtype in Southeast Asia than in North Americ... St. Jude Children,s Research Hospital. , The St....
Other Biology News:Study findings offer potential new targets for antibiotics 2A step toward the $1,000 personal genome using readily available lab equipment 2Drug resistant avian influenza viruses more common in Southeast Asia than North America 2Drug resistant avian influenza viruses more common in Southeast Asia than North America 3Drug resistant avian influenza viruses more common in Southeast Asia than North America 4
Human Phospho-MAPK Array Kit from R&D Systems
...lone d1-174 GenBank Accession Number : NM_006225 ...sion protein corresponding to full length rat PLC ...15M NaCl, 0.05% sodium azide before the addition o...luated by immunoblot on RIPA lysates from PC-12 ce...
Rat CXCL7 (NAP-2) ELISA development Kit, DuoSet Economy Pack from R&D Systems
Rat Fas, Unconjugated from R&D Systems
Biology Products: